icad is a medical devices business based in the US. icad shares (ICAD) are listed on the NASDAQ and all prices are listed in US Dollars. icad employs 108 staff and has a trailing 12-month revenue of around $24.5 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.85 |
|---|---|
| 52-week range | $1.05 - $3.97 |
| 50-day moving average | $2.49 |
| 200-day moving average | $1.91 |
| Wall St. target price | $4.88 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.49 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.85 from 2023-09-21
| 1 week (2023-09-15) | -7.04% |
|---|---|
| 1 month (2023-08-22) | -20.26% |
| 3 months (2023-06-22) | 44.53% |
| 6 months (2023-03-22) | 48.00% |
| 1 year (2022-09-22) | -21.28% |
|---|---|
| 2 years (2021-09-22) | -83.04% |
| 3 years (2020-09-22) | 9.02 |
| 5 years (2018-09-21) | 2.99 |
| Revenue TTM | $24.5 million |
|---|---|
| Gross profit TTM | $20.1 million |
| Return on assets TTM | -15.92% |
| Return on equity TTM | -35.19% |
| Profit margin | -51.13% |
| Book value | $1.20 |
| Market Capitalization | $46.9 million |
TTM: trailing 12 months
We're not expecting icad to pay a dividend over the next 12 months.
icad's shares were split on a 1:5 basis on 15 August 2012. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your icad shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for icad shares which in turn could have impacted icad's share price.
Over the last 12 months, icad's shares have ranged in value from as little as $1.05 up to $3.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while icad's is 1.314. This would suggest that icad's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.